Literature DB >> 29455332

Myasthenia Gravis in HIV Positive Girl.

Renu Suthar1, Naveen Sankhyan1, Jyotindra Narayan Goswami1, Deepti Suri2, Anju Gupta2, Pratibha Singhi3,4.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29455332     DOI: 10.1007/s12098-017-2593-9

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  5 in total

1.  HIV-associated myasthenia gravis and impacts of HAART: one case report and a brief review.

Authors:  Wan-Ling Hung; Yu-Hui Lin; Pao-Yu Wang; Ming-Hong Chang
Journal:  Clin Neurol Neurosurg       Date:  2011-05-04       Impact factor: 1.876

2.  Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.

Authors:  T Kuntzer; A Carota; J Novy; M Cavassini; R A Du Pasquier
Journal:  Neurology       Date:  2011-02-22       Impact factor: 9.910

Review 3.  Comorbid HIV and myasthenia gravis: case report and review of the literature.

Authors:  Lisa Knopf; Daniel L Menkes
Journal:  J Clin Neuromuscul Dis       Date:  2010-12

Review 4.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

5.  Myasthenia gravis associated with human T-cell lymphotropic virus type III infection.

Authors:  H B Wessel; B J Zitelli
Journal:  Pediatr Neurol       Date:  1987 Jul-Aug       Impact factor: 3.372

  5 in total
  2 in total

1.  Case Report: Orbital Myositis and Myasthenia Gravis as Symptoms of Immune Reconstitution Inflammatory Syndrome in a Patient With Human Immunodeficiency Virus Infection.

Authors:  Yanli Wang; Ning Zhao; Jun Yang; Ying Wen
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

Review 2.  TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE.

Authors:  Sven Županić; Ines Lazibat; Maja Rubinić Majdak; Mia Jeličić
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.932

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.